Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome.

Brito-Zerón P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, Dörner T, Gottenberg JE, Kruize AA, Mandl T, Ng WF, Seror R, Tzioufas AG, Vitali C, Bowman S, Mariette X, Ramos-Casals M.

RMD Open. 2019 Oct 28;5(2):e001064. doi: 10.1136/rmdopen-2019-001064. eCollection 2019. Review.

2.

EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.

Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Retamozo S, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vitali C, Bowman S, Mariette X; EULAR-Sjögren Syndrome Task Force Group.

Ann Rheum Dis. 2019 Oct 31. pii: annrheumdis-2019-216114. doi: 10.1136/annrheumdis-2019-216114. [Epub ahead of print]

PMID:
31672775
3.

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR).

Ramos-Casals M, Maria A, Suárez-Almazor ME, Lambotte O, Fisher BA, Hernández-Molina G, Guilpain P, Pundole X, Flores-Chávez A, Baldini C, Bingham Iii CO, Brito-Zerón P, Gottenberg JE, Kostine M, Radstake TRD, Schaeverbeke T, Schulze-Koops H, Calabrese L, Khamashta MA, Mariette X; ICIR.

Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):114-122. Epub 2019 Aug 28.

4.

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.

Virone A, Bastard JP, Fellahi S, Capeau J, Rouanet S, Sibilia J, Ravaud P, Berenbaum F, Gottenberg JE, Sellam J.

RMD Open. 2019 Jul 21;5(2):e000897. doi: 10.1136/rmdopen-2019-000897. eCollection 2019.

5.

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T.

JAMA. 2019 Jul 23;322(4):315-325. doi: 10.1001/jama.2019.9055.

PMID:
31334793
6.

Serum level of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is a biomarker of synovitis in rheumatoid arthritis.

Gorlier C, Gottenberg JE, Laurans L, Simon T, Ait-Oufella H, Sellam J.

Int J Rheum Dis. 2019 Sep;22(9):1616-1618. doi: 10.1111/1756-185X.13656. Epub 2019 Jul 16. No abstract available.

PMID:
31309716
7.

T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients.

Poindron V, Chatelus E, Canuet M, Gottenberg JE, Arnaud L, Gangi A, Gavand PE, Guffroy A, Korganow AS, Germain P, Sibilia J, El Ghannudi S, Martin T.

Semin Arthritis Rheum. 2019 Jun 19. pii: S0049-0172(18)30711-X. doi: 10.1016/j.semarthrit.2019.06.013. [Epub ahead of print]

8.

Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial.

Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, Mariette X, Versnel MA.

Rheumatology (Oxford). 2019 Jun 25. pii: kez242. doi: 10.1093/rheumatology/kez242. [Epub ahead of print]

PMID:
31237947
9.

Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjögren's Syndrome.

Sanosyan A, Daien C, Nutz A, Bollore K, Bedin AS, Morel J, Zimmermann V, Nocturne G, Peries M, Guigue N, Gottenberg JE, Van de Perre P, Mariette X, Tuaillon E.

Front Immunol. 2019 May 29;10:1153. doi: 10.3389/fimmu.2019.01153. eCollection 2019.

10.

Treatment of Sjögren's syndrome: current therapy and future directions.

Fox RI, Fox CM, Gottenberg JE, Dörner T.

Rheumatology (Oxford). 2019 Apr 26. pii: kez142. doi: 10.1093/rheumatology/kez142. [Epub ahead of print]

PMID:
31034046
11.

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials.

Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L.

Autoimmun Rev. 2019 Jun;18(6):576-582. doi: 10.1016/j.autrev.2018.12.008. Epub 2019 Apr 6.

PMID:
30959220
12.

Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity.

Matuszak J, Blondet C, Hubelé F, Gottenberg JE, Sibilia J, Bund C, Geny B, Namer IJ, Meyer A.

Rheumatology (Oxford). 2019 Mar 8. pii: kez040. doi: 10.1093/rheumatology/kez040. [Epub ahead of print]

PMID:
30851092
13.

The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding.

Mouasni S, Gonzalez V, Schmitt A, Bennana E, Guillonneau F, Mistou S, Avouac J, Ea HK, Devauchelle V, Gottenberg JE, Chiocchia G, Tourneur L.

Cell Death Dis. 2019 Feb 25;10(3):190. doi: 10.1038/s41419-019-1412-9.

14.

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.

BMJ. 2019 Jan 24;364:l67. doi: 10.1136/bmj.l67.

15.

Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?

Kostine M, Cappelli LC, Calabrese C, Calabrese LH, Bingham CO 3rd, Richez C, Gottenberg JE, Lambotte O.

Ann Rheum Dis. 2019 Jun;78(6):860-862. doi: 10.1136/annrheumdis-2018-214748. Epub 2019 Jan 18. No abstract available.

PMID:
30659050
16.

A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients.

Luxembourger C, Ruyssen-Witrand A, Ladhari C, Rittore C, Degboe Y, Maillefert JF, Gaudin P, Marotte H, Wendling D, Jorgensen C, Cantagrel A, Constantin A, Nigon D, Touitou I, Gottenberg JE, Pers YM.

Pharmacogenomics J. 2019 Aug;19(4):368-374. doi: 10.1038/s41397-019-0072-6. Epub 2019 Jan 16.

PMID:
30647443
17.

Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?

Anquetil C, Hachulla E, Machuron F, Mariette X, Le Guern V, Vittecoq O, Dernis E, Larroche C, Dubost JJ, Perdriger A, Devauchelle-Pensec V, Fauchais AL, Morel J, Dieudé P, Rist S, Sene D, Gottenberg JE, Hatron PY.

Rheumatology (Oxford). 2019 Jul 1;58(7):1163-1167. doi: 10.1093/rheumatology/key392.

PMID:
30561748
18.

The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis.

Mertz P, Belot A, Cervera R, Chuah TY, Dagna L, Damian L, Danda D, D'cruz D, Espinosa G, Frances C, Jayne D, Ooi KK, Kucharz EJ, Lebovics R, Marie I, Moulis G, Peng S, Sharma A, Suzuki N, Tanaka T, Van Vollenhoven R, Sibilia J, Gottenberg JE, Chasset F, Arnaud L.

Joint Bone Spine. 2019 May;86(3):363-368. doi: 10.1016/j.jbspin.2018.11.001. Epub 2018 Nov 15.

PMID:
30448476
19.

Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature.

Rinagel M, Chatelus E, Jousse-Joulin S, Sibilia J, Gottenberg JE, Chasset F, Arnaud L.

Autoimmun Rev. 2019 Jan;18(1):56-61. doi: 10.1016/j.autrev.2018.07.012. Epub 2018 Nov 5.

PMID:
30408588
20.

Sjögren's syndrome: state of the art on clinical practice guidelines.

Romão VC, Talarico R, Scirè CA, Vieira A, Alexander T, Baldini C, Gottenberg JE, Gruner H, Hachulla E, Mouthon L, Orlandi M, Pamfil C, Pineton de Chambrun M, Taglietti M, Toplak N, van Daele P, van Laar JM, Bombardieri S, Schneider M, Smith V, Cutolo M, Mosca M, Mariette X.

RMD Open. 2018 Oct 18;4(Suppl 1):e000789. doi: 10.1136/rmdopen-2018-000789. eCollection 2018.

21.

Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFα treatment.

Nguyen MVC, Adrait A, Baillet A, Trocmé C, Gottenberg JE, Gaudin P.

Joint Bone Spine. 2019 May;86(3):401-403. doi: 10.1016/j.jbspin.2018.09.005. Epub 2018 Sep 19. No abstract available.

PMID:
30243783
22.

How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project).

Brito-Zerón P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, Seror R, Li X, Baldini C, Gottenberg JE, Danda D, Quartuccio L, Priori R, Hernandez-Molina G, Armagan B, Kruize AA, Kwok SK, Kvarnström M, Praprotnik S, Sène D, Bartoloni E, Solans R, Rischmueller M, Suzuki Y, Isenberg DA, Valim V, Wiland P, Nordmark G, Fraile G, Bootsma H, Nakamura T, Giacomelli R, Devauchelle-Pensec V, Knopf A, Bombardieri M, Trevisani VF, Hammenfors D, Pasoto SG, Retamozo S, Gheita TA, Atzeni F, Morel J, Vollenveider C, Horvath IF, Sivils KL, Olsson P, De Vita S, Sánchez-Guerrero J, Kilic L, Wahren-Herlenius M, Mariette X, Ramos-Casals M; Sjögren Big Data Consortium.

Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):102-112. Epub 2018 Aug 14.

23.

Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells.

Sawaf M, Fauny JD, Felten R, Sagez F, Gottenberg JE, Dumortier H, Monneaux F.

JCI Insight. 2018 Jul 12;3(13). pii: 99711. doi: 10.1172/jci.insight.99711.

24.

Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.

Rietveld A, van den Hoogen LL, Bizzaro N, Blokland SLM, Dähnrich C, Gottenberg JE, Houen G, Johannsen N, Mandl T, Meyer A, Nielsen CT, Olsson P, van Roon J, Schlumberger W, van Engelen BGM, Saris CGJ, Pruijn GJM.

Front Immunol. 2018 Jun 5;9:1200. doi: 10.3389/fimmu.2018.01200. eCollection 2018.

25.

The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials.

Felten R, Dervovic E, Chasset F, Gottenberg JE, Sibilia J, Scher F, Arnaud L.

Autoimmun Rev. 2018 Aug;17(8):781-790. doi: 10.1016/j.autrev.2018.02.011. Epub 2018 Jun 6. Review.

PMID:
29885544
26.

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.

Rivière E, Sellam J, Pascaud J, Ravaud P, Gottenberg JE, Mariette X.

Arthritis Res Ther. 2018 Jun 8;20(1):122. doi: 10.1186/s13075-018-1628-6.

27.

Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients.

Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constans J, Alric L, Jego P, Busato F, Cabon M, Dhote R, Estibaliz L, Koné-Paut I, Landron C, Lavigne C, Lioger B, Michaud M, Ruivard M, Sacre K, Gottenberg JE, Gaches F, Goulenok T, Salvarani C, Cacoub P, Fain O, Saadoun D; French Takayasu network.

J Autoimmun. 2018 Jul;91:55-60. doi: 10.1016/j.jaut.2018.04.002. Epub 2018 Apr 17.

PMID:
29678346
28.

Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus.

Gies V, Schickel JN, Jung S, Joublin A, Glauzy S, Knapp AM, Soley A, Poindron V, Guffroy A, Choi JY, Gottenberg JE, Anolik JH, Martin T, Soulas-Sprauel P, Meffre E, Korganow AS.

JCI Insight. 2018 Mar 8;3(5). pii: 96795. doi: 10.1172/jci.insight.96795.

29.

Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients.

Danion F, Sparsa L, Arnaud L, Alsaleh G, Lefebvre F, Gies V, Martin T, Lukas C, Durckel J, Ardizzone M, Javier RM, Kleinmann JF, Moreau P, Blaison G, Goetz J, Chatelus E, Gottenberg JE, Sibilia J, Sordet C.

RMD Open. 2017 Dec 29;3(2):e000555. doi: 10.1136/rmdopen-2017-000555. eCollection 2017.

30.

Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.

Gottenberg JE, Dörner T, Bootsma H, Devauchelle-Pensec V, Bowman SJ, Mariette X, Bartz H, Oortgiesen M, Shock A, Koetse W, Galateanu C, Bongardt S, Wegener WA, Goldenberg DM, Meno-Tetang G, Kosutic G, Gordon C.

Arthritis Rheumatol. 2018 May;70(5):763-773. doi: 10.1002/art.40425. Epub 2018 Apr 12.

31.

Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.

Henry J, Gottenberg JE, Rouanet S, Pavy S, Sellam J, Tubach F, Belkhir R, Mariette X, Seror R; Auto-Immunity and Rituximab investigators.

Rheumatology (Oxford). 2018 Mar 1;57(3):538-547. doi: 10.1093/rheumatology/kex446.

PMID:
29267905
32.

Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.

Serris A, Amoura Z, Canouï-Poitrine F, Terrier B, Hachulla E, Costedoat-Chalumeau N, Papo T, Lambotte O, Saadoun D, Hié M, Blanche P, Lioger B, Gottenberg JE, Godeau B, Michel M.

Am J Hematol. 2018 Mar;93(3):424-429. doi: 10.1002/ajh.24999. Epub 2018 Jan 25.

33.

Corrigendum to "Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome" [Clin. Immunol. 168 (2016) 25-29].

Harris VM, Sharma R, Cavett J, Kurien BT, Liu K, Koelsch KA, Rasmussen A, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Alarcon-Riquelme ME, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Xie G, Siminovitch KA, Ng WF, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Mariette X, Lessard CJ, Harley JB, Sivils KL, Scofield RH.

Clin Immunol. 2018 Feb;187:137-138. doi: 10.1016/j.clim.2017.11.012. Epub 2017 Dec 7. No abstract available.

PMID:
29195081
34.

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the 'ORA' registry.

Nourisson C, Soubrier M, Mulliez A, Baillet A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Schaeverbeke T, Sibilia J, Vittecoq O, Ravaud P, Gottenberg JE, Mariette X, Tournadre A.

RMD Open. 2017 Nov 1;3(2):e000515. doi: 10.1136/rmdopen-2017-000515. eCollection 2017.

35.

Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.

Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE; French Society of Rheumatology.

Rheumatology (Oxford). 2018 Jan 1;57(1):134-139. doi: 10.1093/rheumatology/kex403.

PMID:
29069471
36.

Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE.

Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, Combe B, Gottenberg JE, Schaeverbeke T, Soubrier M, Vittecoq O, Dougados M, Saraux A, Mariette X, Ravaud P, Sibilia J.

Rheumatology (Oxford). 2017 Oct 1;56(10):1746-1754. doi: 10.1093/rheumatology/kex238.

PMID:
28957557
37.

History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs.

Andrès E, Mourot-Cottet R, Maloisel F, Keller O, Vogel T, Séverac F, Tebacher M, Gottenberg JE, Weber JC, Kaltenbach G, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

J Clin Med. 2017 Sep 26;6(10). pii: E92. doi: 10.3390/jcm6100092.

38.

Role of the IL-12/IL-35 balance in patients with Sjögren syndrome.

Fogel O, Rivière E, Seror R, Nocturne G, Boudaoud S, Ly B, Gottenberg JE, Le Guern V, Dubost JJ, Nititham J, Taylor KE, Chanson P, Dieudé P, Criswell LA, Jagla B, Thai A, Mingueneau M, Mariette X, Miceli-Richard C.

J Allergy Clin Immunol. 2018 Jul;142(1):258-268.e5. doi: 10.1016/j.jaci.2017.07.041. Epub 2017 Sep 12.

PMID:
28916184
39.

History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort.

Andrès E, Mourot-Cottet R, Maloisel F, Vogel T, Tebacher M, Gottenberg JE.

Eur J Intern Med. 2017 Dec;46:e13-e14. doi: 10.1016/j.ejim.2017.08.018. Epub 2017 Aug 18. No abstract available.

PMID:
28823525
40.

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.

Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J.

Ann Rheum Dis. 2017 Dec;76(12):2025-2030. doi: 10.1136/annrheumdis-2017-211623. Epub 2017 Aug 19.

41.

Defective Early B Cell Tolerance Checkpoints in Sjögren's Syndrome Patients.

Glauzy S, Sng J, Bannock JM, Gottenberg JE, Korganow AS, Cacoub P, Saadoun D, Meffre E.

Arthritis Rheumatol. 2017 Nov;69(11):2203-2208. doi: 10.1002/art.40215. Epub 2017 Oct 12.

42.

Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome.

Sharma R, Harris VM, Cavett J, Kurien BT, Liu K, Koelsch KA, Fayaaz A, Chaudhari KS, Radfar L, Lewis D, Stone DU, Kaufman CE, Li S, Segal B, Wallace DJ, Weisman MH, Venuturupalli S, Kelly JA, Pons-Estel B, Jonsson R, Lu X, Gottenberg JE, Anaya JM, Cunninghame-Graham DS, Huang AJW, Brennan MT, Hughes P, Alevizos I, Miceli-Richard C, Keystone EC, Bykerk VP, Hirschfield G, Nordmark G, Bucher SM, Eriksson P, Omdal R, Rhodus NL, Rischmueller M, Rohrer M, Wahren-Herlenius M, Witte T, Alarcón-Riquelme M, Mariette X, Lessard CJ, Harley JB, Ng WF, Rasmussen A, Sivils KL, Scofield RH.

Arthritis Rheumatol. 2017 Nov;69(11):2187-2192. doi: 10.1002/art.40207. Epub 2017 Oct 12.

43.

IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis.

Meyer A, Laverny G, Allenbach Y, Grelet E, Ueberschlag V, Echaniz-Laguna A, Lannes B, Alsaleh G, Charles AL, Singh F, Zoll J, Lonsdorfer E, Maurier F, Boyer O, Gottenberg JE, Nicot AS, Laporte J, Benveniste O, Metzger D, Sibilia J, Geny B.

Acta Neuropathol. 2017 Oct;134(4):655-666. doi: 10.1007/s00401-017-1731-9. Epub 2017 Jun 16.

PMID:
28623559
44.

International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus.

Kleinmann JF, Tubach F, Le Guern V, Mathian A, Richez C, Saadoun D, Sacre K, Sellam J, Seror R, Amoura Z, Andres E, Audia S, Bader-Meunier B, Blaison G, Bonnotte B, Cacoub P, Caillard S, Chiche L, Chosidow O, Costedoat-Chalumeau N, Daien C, Daugas E, Derdèche N, Doria A, Fain O, Fakhouri F, Farge D, Gabay C, Guillo S, Hachulla E, Hajjaj-Hassouni N, Hamidou M, Houssiau FA, Jourde-Chiche N, Koné-Paut I, Ladjouz-Rezig A, Lambotte O, Lipsker D, Mariette X, Martin-Silva N, Martin T, Maurier F, Meckenstock R, Mékinian A, Meyer O, Mohamed S, Morel J, Moulin B, Mulleman D, Papo T, Poindron V, Puéchal X, Punzi L, Quartier P, Sailler L, Smail A, Soubrier M, Sparsa A, Tazi-Mezalek Z, Zakraoui L, Zuily S, Sibilia J, Gottenberg JE.

Autoimmun Rev. 2017 Jun;16(6):650-657. doi: 10.1016/j.autrev.2017.04.011. Epub 2017 Apr 18.

PMID:
28434948
45.

A new MHC-linked susceptibility locus for primary Sjögren's syndrome: MICA.

Carapito R, Gottenberg JE, Kotova I, Untrau M, Michel S, Naegely L, Aouadi I, Kwemou M, Paul N, Pichot A, Locke J, Bowman SJ, Griffiths B, Sivils KL, Sibilia J, Inoko H, Micelli-Richard C, Nocturne G, Ota M, Ng WF, Mariette X, Bahram S.

Hum Mol Genet. 2017 Jul 1;26(13):2565-2576. doi: 10.1093/hmg/ddx135.

46.

Inflammatory myopathies: A new landscape.

Meyer A, Lannes B, Goetz J, Echaniz-Laguna A, Lipsker D, Arnaud L, Martin T, Gottenberg JE, Geny B, Sibilia J.

Joint Bone Spine. 2018 Jan;85(1):23-33. doi: 10.1016/j.jbspin.2017.03.005. Epub 2017 Mar 22. Review.

PMID:
28343013
47.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

48.

[Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].

Mallick A, Fautrel B, Sagez F, Sordet C, Javier RM, Petit H, Chatelus E, Rahal N, Gottenberg JE, Sibilia J.

Rev Med Interne. 2017 Apr;38(4):256-263. doi: 10.1016/j.revmed.2016.12.014. Epub 2017 Feb 1. Review. French.

PMID:
28161110
49.

Idiosyncratic drug-induced neutropenia & agranulocytosis.

Andrès E, Mourot-Cottet R, Maloisel F, Séverac F, Keller O, Vogel T, Tebacher M, Weber JC, Kaltenbach G, Gottenberg JE, Goichot B, Sibilia J, Korganow AS, Herbrecht R.

QJM. 2017 Jan 9. pii: hcw220. doi: 10.1093/qjmed/hcw220. [Epub ahead of print]

PMID:
28069912
50.

Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry.

Latourte A, Gottenberg JE, Luxembourger C, Pane I, Claudepierre P, Richette P, Lafforgue P, Combe B, Cantagrel A, Sibilia J, Flipo RM, Gaudin P, Vittecoq O, Schaeverbeke T, Dougados M, Sellam J, Ravaud P, Mariette X, Seror R.

Rheumatology (Oxford). 2017 Apr 1;56(4):629-637. doi: 10.1093/rheumatology/kew476.

PMID:
28053274

Supplemental Content

Loading ...
Support Center